Comparing two drugs butrophanol and butrophanol with dexmeditomedine in postoperative period with patient controlling device for abominal surgeries

Comparing efficacy of Butrophanol with Dexmedetomidine and Butrophanol in Postoperative period with patient controlled analgesia for abdominal surgeries

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/12/029522

Enrollment

Registered

2020-12-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K928- Other specified diseases of the digestive system

Interventions

Intervention1: Butrophanol with dexmeditomidine in postoperative period with patient controlled analgesia for abdminal surgeries.: A total of 0.5 Î¼g/kg Dexmeditomidine will be infused in Group 11 for

Eligibility

Inclusion criteria

Inclusion criteria: •Adult patients aged between 18-60 years of either gender for elective abdominal surgeries under General Anaesthesia. •Patients belonging to ASA Grade Ð? and Ð?Ð? .

Exclusion criteria

Exclusion criteria: •ASA grade of >=III •obesity [body mass index (BMI), >30] •opioid addiction •patients undergoing psychiatric treatment. •uncontrolled hypertension, severe heart disease, conduction abnormality, neuropsychiatric diseases, alcohol abuse • allergy to either Butorphanol or Dexmedetomidine. •Pregnancy. •If patients require rescue analgesia with in 24 h post operatively.

Design outcomes

Primary

Measure	Time frame
â?¢To study and compare the effect whendexmeditomidine is added to butorphanol for PCIA â?¢Dose requirement of butorphanol post operatively, pump press number â?¢Intraoperative and postoperative haemodynamic changes â?¢Complications like respiratory depression, nausea, vomiting, itching, bradycardia, urinary retention â?¢Patient satisfaction Timepoint: Baseline before Induction Induction Intubation 30 mins post Intubation 60 mins post Intubation Extubation 1 h post suregy 2 h post surgery 6 h post surgery 12 h post surgery 24 h post surgery	—

Measure

Time frame

â?¢To study and compare the effect whendexmeditomidine is added to butorphanol for PCIA â?¢Dose requirement of butorphanol post operatively, pump press number â?¢Intraoperative and postoperative haemodynamic changes â?¢Complications like respiratory depression, nausea, vomiting, itching, bradycardia, urinary retention â?¢Patient satisfaction Timepoint: Baseline before Induction Induction Intubation 30 mins post Intubation 60 mins post Intubation Extubation 1 h post suregy 2 h post surgery 6 h post surgery 12 h post surgery 24 h post surgery

—

Secondary

Measure	Time frame
To study and compare the effect whendexmeditomidine is added to butorphanol for PCIA â?¢Dose requirement of butorphanol post operatively, pump press number â?¢Intraoperative and postoperative haemodynamic changes â?¢Complications like respiratory depression, nausea, vomiting, itching, bradycardia, urinary retention â?¢Patient satisfaction Timepoint: Baseline before Induction Induction Intubation 30 mins post Intubation 60 mins post Intubation Extubation 1 h post suregy 2 h post surgery 6 h post surgery 12 h post surgery 24 h post surgery	—

Measure

Time frame

To study and compare the effect whendexmeditomidine is added to butorphanol for PCIA â?¢Dose requirement of butorphanol post operatively, pump press number â?¢Intraoperative and postoperative haemodynamic changes â?¢Complications like respiratory depression, nausea, vomiting, itching, bradycardia, urinary retention â?¢Patient satisfaction Timepoint: Baseline before Induction Induction Intubation 30 mins post Intubation 60 mins post Intubation Extubation 1 h post suregy 2 h post surgery 6 h post surgery 12 h post surgery 24 h post surgery

—

Countries

India

Contacts

Public ContactDr Pratibha S D

BLDEDU

pratibhakaradi@gmail.com9036110082

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026